drugset

drugset / Trial / NCT00073489

A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00073489 ↗

Phase 2 Completed 23 enrolled Astellas Pharma Inc OSI Pharmaceuticals · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.

Timeline

Start: 2001-05
Primary completion: —
Completion: 2003-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CP-461	Small molecule	—	Oral

Indications